Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015246 | 0.87 | MEN1 (0.48) | TSHRCYP3A4MEN1KMT2AHPGD | |
| SCHEMBL1913721 | 0.86 | TSHR (0.67) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL9496224 | 0.84 | TSHR (0.64) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL19348724 | 0.82 | CYP3A4 (0.61) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL29070722 | 0.82 | TSHR (0.61) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL643849 | 0.81 | CA1 (0.52) | TSHRCYP3A4LMNAACHEHPGD | |
| SCHEMBL21582 | 0.80 | TSHR (1.00) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL131412 | 0.80 | TSHR (1.00) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL27393883 | 0.80 | TSHR (1.00) | TSHRCYP3A4MEN1KMT2ALMNA | |
| SCHEMBL10336991 | 0.80 | TSHR (1.00) | TSHRCYP3A4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429770-A | Preparation method of efficient flame-retardant modified unsaturated polyester resin | 中国科学技术大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113336898-A | Preparation method of styrene-free flame-retardant unsaturated polyester resin | 中国科学技术大学 | 2021-09-03 | — | — | CN | claimed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | claimed |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4744667-A2 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | The Queen's University Of Belfast (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-05-22 | — | — | US | disclosed |
| CN-110662542-B | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and efficient and scalable synthesis of novel crystalline forms thereof | 英国贝尔法斯特女王大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-119320417-A | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs, adenosine dinucleotide conjugates, and efficient and scalable synthesis of novel crystalline forms | 英国贝尔法斯特女王大学 | 2025-01-17 | — | — | CN | disclosed |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-01-14 | — | — | US | disclosed |
| US-20230391815-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2023-12-07 | — | — | US | disclosed |
| CN-112442011-B | Prodrug compound and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-4144394-A | FLAME RETARDANTS FOR POLYMERS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4144290-A | Production of bromoaryl chlorophosphates | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-13 | — | — | US | disclosed |
| US-4134877-A | Flame retardant phosphoramidate compositions | MONSANTO COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4124400-A | Flame retardant polymer compositions | MONSANTO COMPANY (US) | 1978-11-07 | — | — | US | disclosed |
| US-4086302-A | FLAME RETARDANTS | MONSANTO COMPANY (US) | 1978-04-25 | — | — | US | disclosed |
| US-4062909-A | FIRE RETARDANTS | MONSANTO COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4030933-A | FOR CELLULOSE ACETATES | CELANESE CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4028481-A | ACTIVATED TITANIUM TRICHLORIDE AND AN ORGANOALUMINUM COMPOUND | MITSUI TOATSU CHEMICALS, INCORPORATED (JA) | 1977-06-07 | — | — | US | disclosed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | TSHR 1536/4885CYP3A4 3598/4885MEN1 1545/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | TSHR 391/4885CYP3A4 2299/4885MEN1 2789/4885 |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | NAPRT, NAMPT, CD38 | TSHR 1536/4885CYP3A4 3598/4885MEN1 1545/4885 |
| US-20230391815-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | TSHR 1536/4885CYP3A4 3598/4885MEN1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.